

File No. OSMCL-QA-MISC-0007-2025 Letter No. 3156 / OSMCL/QA/I-003/2025 Date. 11.04.2025**ORDER**

Ms. Affy Parenterals, H-206, Sector-63, Noida (UP), Pin-201301 was placed with order to supply of item-D08004-Tab. Albendazole (as per IP 2018 addendum 2019) IP 400mg, vide Purchase Order No. CR32323 Dtd.07.12.2024. The firm has supplied the drug in four (04) number of batches to this corporation, out of which all the four (04) batches have been declared as "Not of Standard Quality (NSQ)" by the Govt. Analyst, SDT&RL, Bhubaneswar, Odisha, which have been communicated to the supplier with enclosed copies of test reports vide this office letter no. 2088 Dtd. 04.03.2025 under intimation to The Assistant Drugs Controller-cum-Licensing Authority, HQ-Baddi, Dist-Solan, Himachal Pradesh-173205. The details of the batches of the subject drug and the reason for declaring the said batches as "NSQ" are mentioned below;

Sl. No.	Item Name	Batch No.	Mfg. Dt.	Exp. Dt.	PO. No. with date	Status	SDT&RL, Bhubaneswar Test report	Reason for declaring NSQ	Mfd. By
1.	D08004 - Tab. Albendazole	PGT25013	Jan-2025	Dec-2027	CR32323 Dtd.07.12.2024	NSQ	1070/8/OSMC/24-25	The sample does not confirm to IP Standard in respect to "Dissolution test".	Ms. Affy Parenterals, Vill-Gularwalla, Baddi, Dist.- Solan, (H.P.)-173205
2.	(as per IP 2018 addendum 2019) IP 400mg	PGT25014	Jan-2025	Dec-2027			1073/9/OSMC/24-25		
3.		PGT25015	Jan-2025	Dec-2027			1075/10/OSMC/24-25		
4.		PGT25016	Jan-2025	Dec-2027			1077/11/OSMC/24-25		

In view of the above, Ms. Affy Parenterals was issued with Show Cause Notice (SCN) vide this office letter No.2542, Dt.18.03.2025 seeking explanation within seven (07) days of receipt of the letter as to why the item - D08004 - Tab. Albendazole (as per IP 2018 addendum 2019) IP 400mg, supplied by the firm Ms. Affy Parenterals having manufacturing unit at Vill-Gularwalla, Baddi, Dist.-Solan, (H.P.)-173205, shall not be De-recognised / Debarred in accordance with PO Clause No. 5(h) (ii) read with Bid Condition No. 6.38.1 (ii) of Bid reference No. OSMCL /2024-25/DRUGS-DHS-GEN-GR-I/01.

The firm has failed to furnish any reply to the Show Cause Notice (SCN) within the stipulated time period as required under this office letter no. 2542 Dtd. 18.03.2025 received by the firm on Dtd. 18.03.2025 through mail and physically sent through Indian Speed post with Tracking No.EO871622209IN, which was delivered to the firm on dtd.25.03.2025.

Hence, as per terms and conditions of PO Clause No. 5(h) (ii) read with Bid Clause No. 6.38.1(ii) of Bid Reference No. OSMCL/2024-25/DRUGS-DHS-GEN-GR-I/01, the item-D08004-Tab. Albendazole (as per IP 2018 addendum 2019) IP 400mg supplied by Ms. Affy Parenterals, H-206, Sector-63, Noida (UP), Pin-201301, having manufacturing unit at Vill-Gularwalla, Baddi, Dist.-Solan, (H.P.)-173205, is hereby De-recognised /Debarred, for the item- D08004- Tab. Albendazole (as per IP 2018 addendum 2019) IP 400mg, for a period of three (03) successive years from the date of issue of

this order.

The Performance Security / Bank Guarantee / EMD amount submitted by the firm for the said item is hereby, forfeited & the firm shall not be allowed to participate in the tender process of Odisha State Medical Corporation Ltd. (OSMCL) for the above said item.

Pama Tudu
Dr. Pama Tudu, I.A.S
Managing Director, OSMCL

Memo No. 3157 /Dt. 11.04.2025

Copy forwarded to Ms. Affy Parenterals, H-206, Sector-63, Noida (UP), Pin-201301 for information.

Pama Tudu
Managing Director, OSMCL

Memo No. 3158 /Dt. 11.04.2025

Copy forwarded to the Assistant Drugs Controller -cum-Licensing Authority, HQ-Baddi, Dist.-Solan, Himachal Pradesh-173205 for information and necessary action.

Pama Tudu
Managing Director, OSMCL

Memo No. 3159 /Dt. 11.04.2025

Copy submitted to the Commissioner-cum-Secretary to Govt., H & FW Dept. Odisha, for favour of kind information.

Pama Tudu
Managing Director, OSMCL

Memo No. 3160 /Dt. 11.04.2025

Copy forwarded to DHS/DMET, Odisha for information and necessary action.

Pama Tudu
Managing Director, OSMCL

Memo No. 3161 /Dt. 11.04.2025

Copy forwarded to the Drugs Controller, Odisha for information and necessary action.

Pama Tudu
Managing Director, OSMCL

Memo No. 3162 /Dt. 11.04.2025

Copy forwarded to the GM-Operation (D & S) / GM (F & A), OSMCL for information and necessary action.

Pama Tudu
Managing Director, OSMCL

Memo No. 3163 /Dt. 11.04.2025

Copy forwarded to IT Cell, OSMCL for information and necessary action.

Pama Tudu
Managing Director, OSMCL

